Evolus Inc Stock Performance
| EOLS Stock | USD 11.72 0.19 1.65% |
Evolus has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 1.77, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Evolus will likely underperform. Evolus Inc right now shows a risk of 2.68%. Please confirm Evolus Inc information ratio, potential upside, as well as the relationship between the Potential Upside and rate of daily change , to decide if Evolus Inc will be following its price patterns.
Risk-Adjusted Performance
1 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Evolus Inc are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable essential indicators, Evolus is not utilizing all of its potentials. The latest stock price uproar, may contribute to short-horizon losses for the private investors. ...more
Actual Historical Performance (%)
One Day Return 0.35 | Five Day Return (3.98) | Year To Date Return 15.82 | Ten Year Return 0.61 | All Time Return 0.61 |
1 | Sale by Karah Parschauer of 11931 shares of Evolus | 02/02/2024 |
2 | Acquisition by Sandra Beaver of 13115 shares of Evolus subject to Rule 16b-3 | 02/21/2024 |
3 | Acquisition by Rui Avelar of 13115 shares of Evolus subject to Rule 16b-3 | 02/23/2024 |
4 | Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635 | 03/08/2024 |
5 | Evolus Announces Pricing of 50.0 Million Underwritten Offering of Common Stock | 03/11/2024 |
6 | Disposition of 96566 shares by David Moatazedi of Evolus at 13.9242 subject to Rule 16b-3 | 03/19/2024 |
7 | Disposition of 27603 shares by Rui Avelar of Evolus at 13.9242 subject to Rule 16b-3 | 03/21/2024 |
8 | Disposition of 6236 shares by David Moatazedi of Evolus at 13.86 subject to Rule 16b-3 | 03/27/2024 |
9 | Evolus to Participate in the SVB Securities Global Biopharma Conference - The Globe and Mail | 04/04/2024 |
10 | Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for Extra-Strength 40U Formulation of Jeuveau | 04/17/2024 |
11 | When Will Evolus, Inc. Become Profitable | 04/18/2024 |
| Begin Period Cash Flow | 53.9 M |
Evolus |
Evolus Relative Risk vs. Return Landscape
If you would invest 1,163 in Evolus Inc on January 24, 2024 and sell it today you would earn a total of 9.00 from holding Evolus Inc or generate 0.77% return on investment over 90 days. Evolus Inc is currently generating 0.047% in daily expected returns and assumes 2.6837% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Evolus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Evolus Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Evolus' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Evolus Inc, and traders can use it to determine the average amount a Evolus' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0175
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EOLS |
Estimated Market Risk
| 2.68 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Evolus is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Evolus by adding it to a well-diversified portfolio.
Evolus Fundamentals Growth
Evolus Stock prices reflect investors' perceptions of the future prospects and financial health of Evolus, and Evolus fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Evolus Stock performance.
| Return On Equity | -12.79 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.31) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 731.8 M | ||||
| Shares Outstanding | 61.5 M | ||||
| Price To Earning | (5.55) X | ||||
| Price To Book | 17.05 X | ||||
| Price To Sales | 3.68 X | ||||
| Revenue | 202.09 M | ||||
| Gross Profit | 92.73 M | ||||
| EBITDA | (30.24 M) | ||||
| Net Income | (61.69 M) | ||||
| Cash And Equivalents | 84.48 M | ||||
| Cash Per Share | 1.51 X | ||||
| Total Debt | 126.55 M | ||||
| Debt To Equity | 1.59 % | ||||
| Current Ratio | 2.60 X | ||||
| Book Value Per Share | (0.36) X | ||||
| Cash Flow From Operations | (34.01 M) | ||||
| Earnings Per Share | (1.08) X | ||||
| Market Capitalization | 709.07 M | ||||
| Total Asset | 189 M | ||||
| Retained Earnings | (558.98 M) | ||||
| Working Capital | 64.13 M | ||||
| Current Asset | 27.24 M | ||||
| Current Liabilities | 76.8 M | ||||
About Evolus Performance
To evaluate Evolus Inc Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Evolus generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Evolus Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Evolus Inc market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Evolus's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 60.19 | 57.18 | |
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | 2.98 | 3.13 |
Things to note about Evolus Inc performance evaluation
Checking the ongoing alerts about Evolus for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Evolus Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 92.73 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 77.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: When Will Evolus, Inc. Become Profitable |
- Analyzing Evolus' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Evolus' stock is overvalued or undervalued compared to its peers.
- Examining Evolus' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Evolus' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Evolus' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Evolus' stock. These opinions can provide insight into Evolus' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Evolus Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Complementary Tools for Evolus Stock analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is Evolus' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Evolus. If investors know Evolus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Evolus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share 3.55 | Quarterly Revenue Growth 0.398 | Return On Assets (0.12) | Return On Equity (12.79) |
The market value of Evolus Inc is measured differently than its book value, which is the value of Evolus that is recorded on the company's balance sheet. Investors also form their own opinion of Evolus' value that differs from its market value or its book value, called intrinsic value, which is Evolus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Evolus' market value can be influenced by many factors that don't directly affect Evolus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Evolus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Evolus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Evolus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.